Third dose of COVID-19 vaccine restores immune response in patients with haematological malignancies after loss of protective antibody titres

Ondrej Šušol; Barbora Hájková; Hana Zelená; Roman Hájek

doi:10.1111/bjh.18073

Third dose of COVID-19 vaccine restores immune response in patients with haematological malignancies after loss of protective antibody titres

Br J Haematol. 2022 May;197(3):302-305. doi: 10.1111/bjh.18073. Epub 2022 Feb 28.

Authors

Ondrej Šušol^{1

2}, Barbora Hájková¹, Hana Zelená³, Roman Hájek^{1

2}

Affiliations

¹ Department of Haemato-oncology, University Hospital Ostrava, Ostrava, Czech Republic.
² Faculty of Medicine, University of Ostrava, Ostrava, Czech Republic.
³ Institute of Public Health, Ostrava, Czech Republic.

PMID: 35076937
DOI: 10.1111/bjh.18073

Abstract

We have vaccinated 392 patients with two doses of mRNA COMIRNATY vaccine with an overall antibody response of 70% (best in cMPN, worst in CLL). We have then vaccinated 80 patients who did not achieve seroconversion or were low responders with a third dose of COMIRNATY vaccine. Our first results show promise, especially for patients on anti-CD38 therapy.

Keywords: 3rd dose; COVID-19; coronavirus; haematological oncology; vaccination; vaccine.

MeSH terms

Antibodies, Viral
Antibody Formation
BNT162 Vaccine
COVID-19 Vaccines
COVID-19* / prevention & control
Hematologic Neoplasms* / therapy
Humans
SARS-CoV-2

Substances

Antibodies, Viral
COVID-19 Vaccines
BNT162 Vaccine